Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Today Asia, Tomorrow The World? AstraZeneca Looks To Align R&D Strategy Across Emerging Markets

This article was originally published in PharmAsia News

Executive Summary

WASHINGTON - AstraZeneca PLC is looking to leverage its experience in Asia to catch up with competitors in other fast growing emerging markets like Russia and Brazil, according to Steve Yang, the company's head of R&D in Asia and emerging markets. Yang, who joined AZ in January, is based in Shanghai and reports to R&D President Martin Mackay

You may also be interested in...



AstraZeneca Goes Deeper Into China Cardiovascular Focus With Tianjin Medical University Agreement

AstraZeneca has signed a collaboration agreement with Chinese research institution Tianjin Medical University to co-explore novel targets against cardiac fibrosis. The agreement builds on a string of such academic collaborations in the country focused on growing chronic diseases.

AstraZeneca Forms Research Alliance In China For Chronic Kidney Disease

To bring new treatment for 112 million patients with kidney disease in China, AstraZeneca is establishing a research collaboration with Shenzhen University to discover new medicines for diabetic nephropathy.

AstraZeneca Forms Research Alliance In China For Chronic Kidney Disease

To bring new treatment for 112 million patients with kidney disease in China, AstraZeneca is establishing a research collaboration with Shenzhen University to discover new medicines for diabetic nephropathy.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC078577

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel